Subscribe To

Price Alert Latest News Economic Calendar News

RVTY / Revvity (RVTY) Launches Single Solution for Drug Development

Revvity (RVTY) Signals Software suite integrates streamlining data, global monitoring and customizable workflows and covers the entire Make-Test-Decide lifecycle, which can be centrally managed. Read More

Demo Live Account See Partner Details

Content Topics

Revvity

RVTY

Launches

Single

Solution

Drug

Development

rvty

Stock

Posted: Jun 13 2023, 13:18

Author Name: Zacks Investment Research

RVTY News

By The Motley Fool
October 30, 2023

Why Revvity Stock Plunged Today

Revvity announced weaker-than-expected third-quarter results and lowered its full-year outlook. CEO Prahlad Singh blamed today's "increasingly challen

By Zacks Investment Research
October 30, 2023

Revvity (RVTY) Misses on Q3 Earnings, Lowers '23 EPS View

Revvity's (RVTY) third-quarter results reflect the impact of increased market uncertainty. The company's earnings and sales miss their respective esti

By Proactive Investors
October 30, 2023

Revvity tumbles on 3Q earnings miss; revised guidance in “increasingly challenging” environment

Revvity Inc posted third-quarter revenue and earnings that fell short of market expectations and lowered its full-year guidance in what it described a

By Zacks Investment Research
October 30, 2023

Revvity (RVTY) Misses Q3 Earnings and Revenue Estimates

Revvity (RVTY) came out with quarterly earnings of $1.18 per share, missing the Zacks Consensus Estimate of $1.19 per share. This compares to earnings

By Reuters
October 30, 2023

Revvity cuts annual forecast on weak demand for diagnostics, contract research

Revvity Inc cut its full-year sales and revenue forecasts after missing Wall Street estimates for third-quarter results, hurt by weak demand for its s

By Zacks Investment Research
October 19, 2023

Revvity's (RVTY) New Tie-Up to Boost NGS Research Workflow

Revvity's (RVTY) latest partnership is likely to address the workflow-related challenges faced by labs and democratize genomic sequencing.

By Zacks Investment Research
September 6, 2023

Revvity (RVTY) Launches Three New Preclinical Research Systems

Revvity (RVTY) launches new preclinical imaging technologies for breakthrough discoveries. Learn how they can help advance research and boost Revvity'

By Seeking Alpha
August 6, 2023

Revvity, Inc. (RVTY) Q2 2023 Earnings Call Transcript

Revvity, Inc. (NYSE:RVTY ) Q2 2023 Earnings Conference Call August 1, 2023 8:00 AM ET Company Participants Stephen Willoughby - Vice President of Inve

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.